文献速递认知障碍与痴呆帕金森病与运动障碍

氨溴索治疗帕金森病痴呆的随机临床试验

Ambroxol as a Treatment for Parkinson Disease Dementia: A Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2025-06-30

这项52周、2期、双盲、安慰剂对照随机试验纳入55例帕金森病痴呆患者,比较氨溴索低剂量(525 mg/日)、高剂量(1050 mg/日)与安慰剂的安全性和认知疗效。结果显示氨溴索安全、耐受良好并实现靶点 engagement,但未证实对认知的改善作用。

要点

  • 氨溴索在帕金森病痴呆患者中安全且耐受良好。
  • 高剂量氨溴索未显示认知或整体改善优于安慰剂。
  • 氨溴索组胃肠道不良事件比例高于安慰剂组。

核心结论

  • 氨溴索在帕金森病痴呆中安全、耐受良好并显示靶点 engagement,但认知疗效未获证实。

研究设计与样本

  • 52周、2期、双盲、安慰剂对照随机临床试验,2015年2月至2023年6月单中心开展。

主要发现

  • 氨溴索组胃肠道不良事件为23/193(12%),安慰剂组为9/172(5%)。
  • 高剂量氨溴索与安慰剂在主要和次要结局上无差异证据。
  • 滴定结束时高剂量氨溴索血浆浓度为7.48μM(SD 3.17μM;95% CI 6.08-8.87μM),脑脊液浓度为0.73μM(SD 0.07μM;95% CI 0.64-0.81μM)。

临床怎么用

  • 现有证据不支持氨溴索用于改善帕金森病痴呆患者的认知,需关注其胃肠道不良反应。

局限性

  • 单中心、样本量小(随机55例),统计比较仅针对高剂量氨溴索与安慰剂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Carrying a variation in the gene for β-glucocerebrosidase is a major risk factor for Parkinson disease dementia (PDD), and raising β-glucocerebrosidase levels lowers α-synuclein in cell and animals. Ambroxol is a chaperone for β-glucocerebrosidase, which increases the levels of β-glucocerebrosidase. OBJECTIVE: To examine the safety and tolerability of ambroxol in PDD, test the efficacy of ambroxol in improving or slowing the progression of cognitive deficits, and acquire pharmacological data. DESIGN, SETTING, AND PARTICIPANTS: This was a 52-week, phase 2, double-blind, placebo-controlled, randomized clinical trial conducted from February 2015 to June 2023. The study took place at a single center and was referral based. Included were patients with PDD who were older than 50 years, had Parkinson disease for at least 1 year before cognitive impairment, had mild to moderate dementia, were taking stable medications, and had a study partner. INTERVENTIONS: Ambroxol low dose (525 mg per day), high dose (1050 mg per day), or placebo. MAIN OUTCOMES AND MEASURES: Safety and tolerability outcomes were adverse events. Primary efficacy outcomes were the Alzheimer Disease Assessment Scale-cognitive subscale, version 13 (ADAS-Cog-13) and Clinician's Global Impression of Change (CGIC). RESULTS: A total of 75 patients were screened, and 55 were randomized. Thirty-one individuals received ambroxol, with 8 patients (mean [SD] age, 78.8 [3.4] years, all male) in the low-dose group and 22 patients (mean [SD] age, 70.7 [7.6]; 19 male [86.4%]) in the high-dose group. One patient was excluded from the high-dose group due to a diagnosis of progressive supranuclear palsy. A total of 24 patients (mean [SD] age, 72.7 [6.3] years; 19 male [79.2%]) were included in the placebo group. Participants receiving ambroxol (23 of 193 adverse events [12%]) showed more gastrointestinal adverse events than those receiving placebo (9 of 172 adverse events [5%]). Statistical analyses compared ambroxol high dose vs placebo. There was no evidence to suggest differences between groups on primary or secondary outcomes. Mean (SD) ambroxol high-dose concentrations were 7.48μM (3.17μM; 95% CI, 6.08-8.87μM) in plasma and 0.73μM (0.07μM; 95% CI, 0.64-0.81μM) in cerebrospinal fluid at the end of titration. Mean (SD) β-glucocerebrosidase levels were higher at week 26 (ambroxol, 12.45 [1.97] nmol/h/mg; 91% CI, 11.54-13.36 nmol/h/mg); placebo, 8.50 [1.96] nmol/h/mg; 91% CI, 7.65-9.34 nmol/h/mg; P = .05) in the ambroxol group compared with placebo. CONCLUSIONS AND RELEVANCE: Results of this randomized clinical trial reveal that ambroxol was safe, well-tolerated, and demonstrated target engagement. However, the effect of ambroxol on cognition was not confirmed. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02914366.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Silveira CRA, Coleman KKL, Borron K, et al. Ambroxol as a Treatment for Parkinson Disease Dementia: A Randomized Clinical Trial. JAMA Neurol. 2025. PMID: 40587145. doi:10.1001/jamaneurol.2025.1687

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。